Exercise helps stave off Alzheimer’s disease, but exactly how it does so is murky. In the February 18 Cell, scientists led by Saul Villeda at the University of California, San Francisco, offered one ...

Can AI bring more order to amyloid scans? In the February 11 Alzheimer’s & Dementia, scientists led by Pierrick Bourgeat at CSIRO Australian eHealth Research Center, Brisbane, and Vincent Doré of ...

Post-marketing data chart immunotherapy performance in early-onset Alzheimer’s. The antibodies lowered amyloid and slowed functional decline. However, tangles continued to form. “These results offer ...

This database is a repository of normal genetic variability, designed to be a tool for researchers who study neurodegenerative disease. It contains whole-exome sequencing results from nearly 500 ...

As the brain’s fluid drainage systems become sluggish with age, troublemakers such as amyloid and tau aggregates start to build up. To flush out disease-causing detritus, neurosurgeons in China have ...

According to a recent study, the view that Alzheimer’s disease damages the brain irreversibly might need to change. In December 22 Cell Reports Medicine online, scientists led by Andrew Pieper of Case ...

On November 24, Novo Nordisk announced that the GLP-1 mimetic semaglutide had failed to slow progression of Alzheimer’s disease in two Phase 3 trials. Even though the cat was out of the bag, ...

Back in July, the U.S. POINTER study showed that a structured lifestyle makeover in older adults slightly improves scores on memory and thinking tests (Baker et al., 2025; Aug 2025 conference news).

Transferrin-receptor shuttles distribute antibody cargo throughout the parenchyma, steering clear of ARIA-provoking vascular amyloid. Trontinemab is enrolling Phase 3 for early AD, announces plans for ...

Some evidence suggests that regular consumption of fish, nuts, fruits, veggies, and whole grains, aka the Mediterranean diet, reduces a person’s risk of dementia. APOE4, on the other hand, increases ...

The current Alzheimer’s disease therapeutic antibodies carry a sizable risk of ARIA, especially for APOE4 carriers. Researchers believe the future of amyloid immunotherapies lies in targeted brain ...

With two amyloid immunotherapies on the market in many countries, scientists are eager for information on how durable their clinical effects will be. At this year’s Alzheimer’s Association ...